Inspire Medical Systems (NYSE:INSP) Price Target Cut to $70.00 by Analysts at Truist Financial

Inspire Medical Systems (NYSE:INSP) had its target price reduced by stock analysts at Truist Financial from $96.00 to $70.00 in a report issued on Thursday,Benzinga reports. The firm currently has a “hold” rating on the stock. Truist Financial’s price target suggests a potential upside of 2.20% from the stock’s previous close.

Other research analysts also recently issued research reports about the stock. Royal Bank Of Canada downgraded shares of Inspire Medical Systems from an “outperform” rating to a “sector perform” rating and decreased their target price for the company from $175.00 to $90.00 in a research report on Tuesday, January 27th. JPMorgan Chase & Co. raised their price objective on Inspire Medical Systems from $82.00 to $118.00 and gave the company a “neutral” rating in a report on Tuesday, December 16th. Wells Fargo & Company set a $70.00 target price on Inspire Medical Systems and gave the company an “equal weight” rating in a research report on Thursday. Mizuho upped their target price on Inspire Medical Systems from $110.00 to $130.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. Finally, Oppenheimer cut Inspire Medical Systems from an “outperform” rating to a “market perform” rating in a research report on Thursday, January 22nd. Six investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $113.94.

Inspire Medical Systems Stock Performance

NYSE INSP opened at $68.50 on Thursday. The stock has a market capitalization of $1.99 billion, a price-to-earnings ratio of 46.60, a PEG ratio of 6.87 and a beta of 0.74. The stock’s 50 day moving average price is $96.03 and its two-hundred day moving average price is $91.70. Inspire Medical Systems has a 52 week low of $64.46 and a 52 week high of $197.75.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings results on Wednesday, February 11th. The company reported $1.65 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.96. Inspire Medical Systems had a net margin of 5.05% and a return on equity of 9.41%. The company had revenue of $269.08 million during the quarter, compared to analysts’ expectations of $264.02 million. During the same period last year, the business earned $1.15 EPS. The business’s quarterly revenue was up 12.2% on a year-over-year basis. On average, equities research analysts forecast that Inspire Medical Systems will post 2.16 EPS for the current year.

Insider Transactions at Inspire Medical Systems

In other Inspire Medical Systems news, Director Shawn Mccormick sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $127.48, for a total value of $254,960.00. Following the sale, the director owned 26,046 shares in the company, valued at $3,320,344.08. This represents a 7.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 4.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Inspire Medical Systems

A number of large investors have recently added to or reduced their stakes in the business. Royal Bank of Canada boosted its position in Inspire Medical Systems by 16.0% during the first quarter. Royal Bank of Canada now owns 32,769 shares of the company’s stock worth $5,220,000 after purchasing an additional 4,528 shares during the period. Integrated Wealth Concepts LLC bought a new position in shares of Inspire Medical Systems in the first quarter valued at about $524,000. Goldman Sachs Group Inc. lifted its stake in shares of Inspire Medical Systems by 57.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 51,422 shares of the company’s stock worth $8,190,000 after buying an additional 18,857 shares during the last quarter. Janney Montgomery Scott LLC boosted its holdings in shares of Inspire Medical Systems by 22.7% during the 2nd quarter. Janney Montgomery Scott LLC now owns 5,316 shares of the company’s stock worth $690,000 after buying an additional 984 shares during the period. Finally, KLP Kapitalforvaltning AS boosted its holdings in shares of Inspire Medical Systems by 10.5% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 6,300 shares of the company’s stock worth $818,000 after buying an additional 600 shares during the period. Institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems News Roundup

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q4 beat: EPS of $1.65 vs. Street ~$0.70 and revenue of $269.1M (+12% y/y), showing better-than-expected top- and bottom-line execution. Article Title
• Positive Sentiment: Strong full-year metrics and liquidity: 2025 revenue $912M (+14%), operating cash flow $117M, and $175M in share repurchases — supports cash generation and shareholder return capacity. Article Title
• Neutral Sentiment: Management commentary and detail available — full earnings-call transcript and slide deck provide color on Inspire V adoption, payer engagement and margin assumptions for 2026. Useful for modeling scenarios and hearing management’s mitigation plans. Article Title
• Negative Sentiment: Coding & reimbursement risk: Company said recent coding clarification points clinicians to CPT 64582 with a -52 modifier for Inspire V, which may lower physician reimbursement and slow procedure adoption; as a result management narrowed/revised 2026 revenue guidance to $950M–$1.0B (growth ~4%–10%), reflecting meaningful uncertainty. Article Title
• Negative Sentiment: Market reaction and positioning: Shares reportedly slid after the coding/guidance update (coverage noted a roughly 8% drop) and short interest rose materially in January to ~13.6% of float (up ~31%), increasing downside pressure and potential volatility. Article Title

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.